Pyxis Oncology (NASDAQ:PYXS) is a precision oncology company dedicated to advancing personalized cancer treatments through biomarker-driven insights. The company specializes in the discovery, development and commercialization of diagnostic assays that profile the tumor microenvironment and genomic alterations associated with immuno-oncology and targeted therapies. Utilizing proprietary ex vivo functional assays and next-generation sequencing platforms, Pyxis Oncology identifies determinants of drug response and resistance to inform clinical trial design and therapeutic strategies.
Pyxis Oncology’s product portfolio includes tissue-based and liquid biopsy assays designed to measure immune cell functionality, cytokine release and tumor-specific genetic mutations. Key services encompass functional immunoprofiling to evaluate patient response to immunotherapies, comprehensive genomic profiling to detect actionable mutations, and companion diagnostic development in collaboration with biopharmaceutical partners. The company’s integrated approach leverages high-throughput biomarker screening and data analytics to accelerate go-to-market timelines for novel oncology therapeutics.
Founded in 2020 and headquartered in the Boston metropolitan area, Pyxis Oncology operates state-of-the-art laboratories in North America and maintains partnerships across Europe and Asia to support global drug development programs. Leveraging a multidisciplinary team of immunologists, molecular biologists and bioinformaticians, the company aims to bridge the gap between laboratory research and clinical application, empowering oncologists with deeper insights into treatment mechanisms.
Under the leadership of CEO David J. Jung, M.D., M.B.A., and Chief Scientific Officer Audrey Kunzelmann, Ph.D., Pyxis Oncology has rapidly expanded its footprint in the oncology diagnostics space. The company is backed by a consortium of healthcare investors and collaborates with leading academic centers to validate its assays and drive innovation in precision immuno-oncology.
